According to the latest market research study published by P&S Intelligence, the global auto-injectors market was valued at USD 1,011 million in 2023 and is projected to grow at a CAGR of 14.8%, reaching USD 2,640.2 million by 2030.

This substantial growth is driven by the increasing need for ease of drug administration, the rising prevalence of chronic and lifestyle-related diseases, and advancements in healthcare technologies. According to the World Health Organization (WHO), over 16 billion injections are administered annually worldwide, highlighting the necessity for safer and more convenient injection methods.

Key Insights

• The WHO projects a 57% increase in the prevalence of chronic diseases in the coming years, with 60% of this surge expected in emerging markets. Chronic illnesses are major contributors to global disability and morbidity. For instance, in 2020, there were approximately 19.3 million new cancer cases diagnosed globally.
• Diabetes affects around 536 million people aged 20 to 79 worldwide. This number is expected to reach 643 million by 2030 and 783 million by 2045, with three out of every four adults with diabetes living in low- or middle-income countries. ​
• In 2021, approximately 10 million individuals globally contracted tuberculosis, including 5.6 million men, 3.3 million women, and 1.1 million children. The majority of these cases occurred in 30 high-burden countries, with India leading the list, followed by Indonesia, China, Pakistan, the Philippines, Bangladesh, and Nigeria. ​
• Auto-injectors offer significant advantages over traditional syringes, including simplified self-administration, reduced anxiety, enhanced safety, and improved compliance. They minimize the risk of needlestick injuries, which can lead to the transmission of blood-borne pathogens, thereby alleviating anxiety and emotional distress among healthcare workers. ​
• Many countries are enforcing the mandatory use of devices with needlestick prevention features to enhance occupational safety. The WHO manages the Safe Injection Global Network (SIGN) to promote and sustain injection safety worldwide. ​
• The increasing prevalence of chronic diseases necessitates frequent injections for treatment or symptom management, further driving the demand for auto-injectors. For example, rheumatoid arthritis, an autoimmune disease causing joint inflammation, requires regular medication administration, making auto-injectors a convenient option for patients.  

In summary, the auto-injectors market is experiencing robust growth due to the rising incidence of chronic diseases, the need for safer injection methods, and technological advancements in healthcare. These factors collectively contribute to the increasing adoption of auto-injectors globally.